DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments including CAR-T and bispecific antibodies to improve efficacy and safety. Recent developments include FDA approvals, clinical trial progress, and strategic acquisitions, signaling strong growth and innovation in this therapeutic area. The evolving landscape aims to address treatment resistance and improve patient outcomes with next-generation therapies.
Leading pharma companies mentioned in the BCMA therapies report, such as Regeneron, Pfizer, and AstraZeneca, show varied trading activity on Pluang. Regeneron trades at USD 955.23 with a slight 0.44% decline, Pfizer at USD 29.17 down 0.95%, and AstraZeneca at USD 184.46 down 0.55%. These figures are as of Nov 13, 2026 01:11 WIB, reflecting current investor sentiment on Pluang.
Amgen and Regeneron both pay dividends but cater to different retiree needs: Amgen provides a higher, steadily increasing dividend yield of about 2.16%, suitable for retirees needing income now. Regeneron offers a smaller dividend yield of 0.41% but ...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
Regeneron's CIDEB siRNA, a new liver-targeted therapy, showed in a first-in-human trial a rapid and sustained reduction of liver fat by up to 80% in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The treatment also im...
